67848-59-3

Basic information

• Product Name: 4-OXO-PIPERIDINE-3-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 4-OXO-PIPERIDINE-3-CARBOXYLIC ACID ETHYL ESTER;4-Oxo-3-piperidinecarboxylic acid ethyl ester;Ethyl 4-oxo-3-piperidinecarboxylate;3-Piperidinecarboxylic acid, 4-oxo-, ethyl ester
• CAS NO: 67848-59-3
• Molecular Formula: C₈H₁₃NO₃
• Molecular Weight: 171.19
• Product Categories: PHARMACEUTICAL INTERMEDIATES;pharmacetical;API intermediates
• Mol File: 67848-59-3.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 265.5 °C at 760 mmHg
• Flash Point: 114.4 °C
• Appearance: /
• Density: 1.118 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-OXO-PIPERIDINE-3-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-OXO-PIPERIDINE-3-CARBOXYLIC ACID ETHYL ESTER(67848-59-3)
• EPA Substance Registry System: 4-OXO-PIPERIDINE-3-CARBOXYLIC ACID ETHYL ESTER(67848-59-3)

Safety Data

• Hazardous Substances Data: 67848-59-3(Hazardous Substances Data)

Usage

General Description

4-Oxo-piperidine-3-carboxylic acid ethyl ester, also known as 4-oxopiperidine-3-carboxylic acid ethyl ester, is an organic compound that belongs to the class of piperidines. It is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various pharmaceuticals and medicinally active compounds. This chemical is also used as a building block for the production of other organic compounds, such as drugs, agrochemicals, and materials. It is a white to off-white solid, and its molecular structure consists of a piperidine ring with a carboxylic acid ester group attached to it. It is important to handle this compound with care, following proper safety and handling guidelines, due to its potential health and environmental hazards.

InChI:InChI=1S/C8H13NO3/c1-2-12-8(11)6-5-9-4-3-7(6)10/h6,9H,2-5H2,1H3

Upstream product

• 41276-30-6 C₉H₁₄O₃NC₆H₅ 

Downstream Products

• 52834-08-9 4-amino-5-bromonicotinic acid 
• 1052114-83-6 5-bromo-4-hydroxypyridine-3-carboxylic acid 
• 7418-65-7 4-aminonicotinic acid 
• 609-70-1 4-hydroxynicotinic acid 
• 1095717-42-2 2-(1,3-benzodioxol-5-yl)-6-{[(3-ethylphenyl)amino]carbonyl}-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl 4-methylbenzenesulfonate 
• 1095715-84-6 2-(1,3-benzodioxol-5-yl)-N-(3-ethylphenyl)-4-(2-methyphenyl)-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide 
• 1095717-41-1 2-(1,3-benzodioxol-5-yl)-N-(3-ethylphenyl)-4-hydroxy-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxamide 
• 109229-22-3 6-benzyl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4(3H)-one 
• 41276-30-6 C₉H₁₄O₃NC₆H₅ 
• 1026786-82-2 (3'R,4'S)-6-[2-(2,6-dichloro-4-methylphenoxy)ethoxy]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1',3'-dicarboxylic acid 1'-tert-butyl ester 
• 1265907-56-9 C₂₇H₃₄Cl₂N₂O₆ 
• 1206625-70-8 C₂₄H₂₅Cl₂F₃N₂O₅ 
• 1265907-55-8 (3'S,4'S)-6-[2-(2,6-dichloro-4-methyl-phenoxy)ethoxy]-3',4',5',6'-tetrahydro-2'H-[3,4']bipyridinyl-1',3'-dicarboxylic acid 1'-tert-butyl ester 3'-ethyl ester 
• 1206625-88-8 6-[2-(2,6-dichloro-4-methyl-phenoxy)ethoxy]-1'-(2,2,2-trifluoroacetyl)-1',2',5',6'-tetrahydro-[3,4']bipyridinyl-3'-carboxylic acid ethyl ester 

Relevant articles and documents

Optimization and evaluation of novel tetrahydropyrido[4,3-d]pyrimidine derivatives as ATX inhibitors for cardiac and hepatic fibrosis

Aiming to develop potent autotaxin (ATX) inhibitors for fibrosis diseases, a novel series of tetrahydropyrido[4,3-d]pyrimidine derivatives was designed and synthesized based on our previous study. The enzymatic assay combined with anti-proliferative activities against cardiac fibroblasts (CFs) and hepatic stellate cell (HSC) in vitro were applied for preliminary evaluation of anti-fibrosis potency of target compounds, resulting in two outstanding ATX inhibitors 8b and 10g with the IC50 values in a nanomolar range (24.6 and 15.3 nM). Differently, 8b was the most prominent compound against CFs with inhibition ratio of 81.5%, while 10g exhibited the maximum inhibition ratio of 83.7% against t-HSC/Cl-6 cells. In the further pharmacological evaluations in vivo, collagen deposition assay demonstrated the conspicuous capacity of 8b to suppress TGF-β-mediated cardiac fibrosis. Simultaneously, H&E and Masson stains assays of mice liver validated 10g as an excellent anti-hepatofibrosis candidate, which reduced CCl4-induced hepatic fibrosis level prominently. Besides, the molecular binding models identified the essential interactions between 8b and ATX which was coincided with the SARs.

Substituted 1,2,3,4-tetrahydrobenzo[C][2,7] naphthyridines and derivatives thereof as kinase inhibitors

The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.

Design and syntheses of melanocortin subtype-4 receptor agonists. Part 2: Discovery of the dihydropyridazinone motif

Optimization of the biological activity of a new class of non-peptidyl, pyridazinone derived human melanocortin subtype-4 receptor agonists is disclosed.